These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended
August 31, 2013.
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to __________.
|
| CALIFORNIA | 94-2424084 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|
400 KATO TERRACE
FREMONT, CA
|
94539 | |
| (Address of principal executive offices) | (Zip Code) |
| Large accelerated filer | o | Accelerated filer | o |
| Non-accelerated filer | o | Smaller reporting company | þ |
| (Do not check if a smaller reporting company) | |||
| 4 | |||||
|
4
|
|||||
| 5 | |||||
| 6 | |||||
| 7 | |||||
| 8 | |||||
| 16 | |||||
| 20 | |||||
| 20 | |||||
| 21 | |||||
| 21 | |||||
| 28 | |||||
| 28 | |||||
| 28 | |||||
| 28 | |||||
| 28 | |||||
| SIGNATURE PAGE | 29 | ||||
| Index to Exhibits | 30 | ||||
|
August 31,
|
May 31,
|
|||||||
|
2013
|
2013
|
|||||||
| (1) | ||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 2,435 | $ | 2,324 | ||||
|
Accounts receivable, net of allowances for
doubtful accounts of $46
and $39 at
August 31, 2013 and May 31, 2013, respectively
|
2,860 | 2,632 | ||||||
|
Inventories
|
5,369 | 5,369 | ||||||
|
Prepaid expenses and other
|
456 | 197 | ||||||
|
Total current assets
|
11,120 | 10,522 | ||||||
|
Property and equipment, net
|
246 | 301 | ||||||
|
Other assets
|
78 | 152 | ||||||
|
Total assets
|
$ | 11,444 | $ | 10,975 | ||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Line of credit
|
$ | 947 | $ | 1,101 | ||||
|
Accounts payable
|
1,403 | 1,188 | ||||||
|
Accrued expenses
|
1,437 | 1,440 | ||||||
|
Customer deposits and deferred revenue, short-term
|
2,413 | 1,972 | ||||||
|
Total current liabilities
|
6,200 | 5,701 | ||||||
|
Income tax payable
|
76 | 109 | ||||||
|
Deferred lease commitment
|
80 | 103 | ||||||
|
Deferred revenue, long-term
|
36 | 68 | ||||||
|
Total liabilities
|
6,392 | 5,981 | ||||||
|
Aehr Test Systems shareholders' equity:
|
||||||||
|
Common stock, $0.01 par value:
|
||||||||
|
Issued and outstanding: 10,668 shares and
10,599 shares at August 31, 2013 and
May 31, 2013, respectively
|
107 | 106 | ||||||
|
Additional paid-in capital
|
50,781 | 50,580 | ||||||
|
Accumulated other comprehensive income
|
2,465 | 2,442 | ||||||
|
Accumulated deficit
|
(48,280 | ) | (48,114 | ) | ||||
|
Total Aehr Test Systems shareholders' equity
|
5,073 | 5,014 | ||||||
|
Noncontrolling interest
|
(21 | ) | (20 | ) | ||||
|
Total shareholders' equity
|
5,052 | 4,994 | ||||||
|
Total liabilities and shareholders' equity
|
$ | 11,444 | $ | 10,975 | ||||
|
(1)
|
The condensed consolidated balance sheet at May 31, 2013 has been derived from the audited consolidated financial statements at that date.
|
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Net sales
|
$ | 3,752 | $ | 4,832 | ||||
|
Cost of sales
|
1,808 | 2,376 | ||||||
|
Gross profit
|
1,944 | 2,456 | ||||||
|
Operating expenses:
|
||||||||
|
Selling, general and administrative
|
1,420 | 1,789 | ||||||
|
Research and development
|
681 | 930 | ||||||
|
Total operating expenses
|
2,101 | 2,719 | ||||||
|
Loss from operations
|
(157 | ) | (263 | ) | ||||
|
Interest expense
|
(4 | ) | (12 | ) | ||||
|
Other expense, net
|
(34 | ) | (19 | ) | ||||
|
Loss before income tax
benefit (expense)
|
(195 | ) | (294 | ) | ||||
|
Income tax benefit (expense)
|
29 | (2 | ) | |||||
|
Net loss
|
(166 | ) | (296 | ) | ||||
|
Less: Net income attributable to
the noncontrolling interest
|
-- | -- | ||||||
|
Net loss attributable to Aehr
Test Systems common shareholders
|
$ | (166 | ) | $ | (296 | ) | ||
|
Net loss per share – Basic and diluted
|
$ | (0.02 | ) | $ | (0.03 | ) | ||
|
Shares used in per share calculations:
|
||||||||
|
Basic and diluted
|
10,635 | 9,166 | ||||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Net loss
|
$ | (166 | ) | $ | (296 | ) | ||
|
Other comprehensive income, net of tax:
Foreign currency translation gain
|
23 | 15 | ||||||
|
Total comprehensive loss
|
(143 | ) | (281 | ) | ||||
|
Less: Comprehensive income attributable to
noncontrolling interest
|
(1 | ) | -- | |||||
|
Comprehensive loss, attributable to
Aehr Test Systems
|
$ | (144 | ) | $ | (281 | ) | ||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$ | (166 | ) | $ | (296 | ) | ||
|
Adjustments to reconcile net loss to
net cash provided by (used in) operating
activities:
|
||||||||
|
Stock-based compensation expense
|
143 | 169 | ||||||
|
Provision for (recovery of) doubtful accounts
|
7 | (1 | ) | |||||
|
Loss on disposal of assets
|
9 | -- | ||||||
|
Depreciation and amortization
|
53 | 86 | ||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(216 | ) | 53 | |||||
|
Inventories
|
-- | (640 | ) | |||||
|
Prepaid expenses and other
|
(181 | ) | (127 | ) | ||||
|
Accounts payable
|
175 | 485 | ||||||
|
Customer deposits and deferred revenue
|
409 | (162 | ) | |||||
|
Accrued expenses
|
7 | 178 | ||||||
|
Income tax payable
|
(45 | ) | 1 | |||||
|
Deferred lease commitment
|
(23 | ) | (18 | ) | ||||
|
Net cash provided by (used in)
operating activities
|
172 | (272 | ) | |||||
|
Cash flows from investing activities:
|
||||||||
|
Purchase of property and equipment
|
(6 | ) | (16 | ) | ||||
|
Net cash used in
investing activities
|
(6 | ) | (16 | ) | ||||
|
Cash flows from financing activities:
|
||||||||
|
Line of credit (repayments) borrowings, net
|
(154 | ) | 44 | |||||
|
Proceeds from issuance of common stock
and exercise of stock options
|
59 | 67 | ||||||
|
Net cash (used in) provided by
financing activities
|
(95 | ) | 111 | |||||
|
Effect of exchange rates on cash
|
40 | 5 | ||||||
|
Net increase (decrease) in cash and
cash equivalents
|
111 | (172 | ) | |||||
|
Cash and cash equivalents, beginning of period
|
2,324 | 2,073 | ||||||
|
Cash and cash equivalents, end of period
|
$ | 2,435 | $ | 1,901 | ||||
|
Three Months Ended
|
|||||||||
|
August 31,
|
|||||||||
|
2013
|
2012
|
||||||||
|
Stock-based compensation in the form of employee stock options and ESPP shares, included in:
|
|||||||||
|
Cost of sales
|
$ | 8 | $ | 13 | |||||
|
Selling, general and administrative
|
104 | 119 | |||||||
|
Research and development
|
31 | 37 | |||||||
|
Total stock-based compensation
|
$ | 143 | $ | 169 | |||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Option plan shares
|
||||||||
|
Expected term (in years)
|
4 | 5 | ||||||
|
Volatility
|
0.95 | 0.90 | ||||||
|
Expected dividend
|
$ | 0.00 | $ | 0.00 | ||||
|
Risk-free interest rates
|
1.46 | % | 0.75 | % | ||||
|
Estimated forfeiture rate
|
0.25 | % | 0.25 | % | ||||
|
Weighted average grant date fair value
|
$ | 0.92 | $ | 0.88 | ||||
|
Outstanding Options
|
||||||||||||||||
|
Weighted
|
||||||||||||||||
|
Number
|
Average
|
Aggregate
|
||||||||||||||
|
Available
|
of
|
Exercise
|
Intrinsic
|
|||||||||||||
|
Shares
|
Shares
|
Price
|
Value
|
|||||||||||||
|
Balances, May 31, 2013
|
1,737 | 2,956 | $ | 1.79 | $ | 964 | ||||||||||
|
Options granted
|
(725 | ) | 725 | $ | 1.38 | |||||||||||
|
Options terminated
|
289 | (289 | ) | $ | 6.99 | |||||||||||
|
Plan shares expired
|
(104 | ) | -- | |||||||||||||
|
Options exercised
|
-- | (69 | ) | $ | 0.86 | |||||||||||
|
Balances, August 31, 2013
|
1,197 | 3,323 | $ | 1.27 | $ | 1,301 | ||||||||||
|
Options fully vested and expected to vest at August 31, 2013
|
3,257 | $ | 1.27 | $ | 1,275 | |||||||||||
|
Options exercisable at August 31, 2013
|
1,816 | $ | 1.28 | $ | 769 | |||||||||||
|
Options Outstanding
at August 31, 2013
|
Options Exercisable
at August 31, 2013
|
|||||||||||||||||||||||||||||
|
Range of
Exercise
Prices
|
Number
Outstanding
Shares
|
Weighted
Average Remaining Contractual Life (Years) |
Weighted Average Exercise Price
|
Number
Exercisable
Shares
|
Weighted
Average Remaining Contractual Life (Years) |
Weighted Average Exercise Price |
Aggregate
Intrinsic
Value
|
|||||||||||||||||||||||
| $0.59-$0.97 | 1,101 | 3.94 | $ | 0.76 | 846 | 3.51 | $ | 0.80 | ||||||||||||||||||||||
| $1.09-$1.42 | 1,484 | 5.59 | $ | 1.28 | 453 | 4.53 | $ | 1.28 | ||||||||||||||||||||||
| $1.55-$1.95 | 487 | 3.45 | $ | 1.88 | 277 | 2.04 | $ | 1.93 | ||||||||||||||||||||||
| $2.15-$2.52 | 251 | 0.55 | $ | 2.24 | 240 | 0.49 | $ | 2.25 | ||||||||||||||||||||||
| $0.59-$2.52 | 3,323 | 4.35 | $ | 1.27 | 1,816 | 3.14 | $ | 1.28 | $ | 769 | ||||||||||||||||||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Numerator: Net loss
|
$ | (166 | ) | $ | (296 | ) | ||
|
Denominator for basic net loss
per share:
|
||||||||
|
Weighted-average shares outstanding
|
10,635 | 9,166 | ||||||
|
Shares used in basic net loss
per share calculation
|
10,635 | 9,166 | ||||||
|
Effect of dilutive securities
|
-- | -- | ||||||
|
Denominator for diluted net loss
per share
|
10,635 | 9,166 | ||||||
|
Basic net loss per share
|
$ | (0.02 | ) | $ | (0.03 | ) | ||
|
Diluted net loss per share
|
$ | (0.02 | ) | $ | (0.03 | ) | ||
|
Balance as of
|
||||||||||||||||
|
August 31,
2013
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 402 | $ | 402 | $ | -- | $ | -- | ||||||||
|
Assets
|
$ | 402 | $ | 402 | $ | -- | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
Balance as of
|
||||||||||||||||
|
May 31,
2013
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 102 | $ | 102 | $ | -- | $ | -- | ||||||||
|
Assets
|
$ | 102 | $ | 102 | $ | -- | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
August 31,
|
May 31,
|
|||||||
|
2013
|
2013
|
|||||||
|
Raw materials and sub-assemblies
|
$ | 2,739 | $ | 3,180 | ||||
|
Work in process
|
2,429 | 2,187 | ||||||
|
Finished goods
|
201 | 2 | ||||||
| $ | 5,369 | $ | 5,369 | |||||
|
United
|
||||||||||||||||
|
States
|
Asia
|
Europe
|
Total
|
|||||||||||||
|
Three months ended August 31, 2013:
|
||||||||||||||||
|
Net sales
|
$ | 3,605 | $ | 53 | $ | 94 | $ | 3,752 | ||||||||
|
Property and equipment, net
|
202 | 44 | -- | 246 | ||||||||||||
|
Three months ended August 31, 2012:
|
||||||||||||||||
|
Net sales
|
$ | 4,668 | $ | 34 | $ | 130 | $ | 4,832 | ||||||||
|
Property and equipment, net
|
369 | 69 | 1 | 439 | ||||||||||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Balance at the beginning of the period
|
$ | 222 | $ | 91 | ||||
|
Accruals for warranties issued during the period
|
92 | 130 | ||||||
|
|
||||||||
|
Settlement made during the period (in cash or in kind)
|
(88 | ) | (106 | ) | ||||
|
Balance at the end of the period
|
$ | 226 | $ | 115 | ||||
|
August 31,
|
May 31,
|
|||||||
|
2013
|
2013
|
|||||||
|
Customer deposits
|
$ | 2,167 | $ | 1,728 | ||||
|
Deferred revenue, short-term
|
246 | 244 | ||||||
| $ | 2,413 | $ | 1,972 | |||||
|
Three Months Ended
|
||||||||
|
August 31
|
||||||||
|
2013
|
2012
|
|||||||
|
Net sales
|
100.0 | % | 100.0 | % | ||||
|
Cost of sales
|
48.2 | 49.2 | ||||||
|
Gross profit
|
51.8 | 50.8 | ||||||
|
Operating expenses:
|
||||||||
|
Selling, general and administrative
|
37.8 | 37.0 | ||||||
|
Research and development
|
18.2 | 19.2 | ||||||
|
Total operating expenses
|
56.0 | 56.2 | ||||||
|
Loss from operations
|
(4.2 | ) | (5.4 | ) | ||||
|
Interest expense
|
(0.1 | ) | (0.3 | ) | ||||
|
Other expense, net
|
(0.9 | ) | (0.4 | ) | ||||
|
Loss before income tax benefit (expense)
|
(5.2 | ) | (6.1 | ) | ||||
|
Income tax benefit
|
0.8 | -- | ||||||
|
Net loss
|
(4.4 | ) | (6.1 | ) | ||||
|
Less: Net income attributable
to the noncontrolling interest
|
-- | -- | ||||||
|
Net loss attributable to Aehr
Test Systems common shareholders
|
(4.4 | )% | (6.1 | )% | ||||
| Aehr Test Systems | |||
| (Registrant) | |||
|
Date: October 15, 2013
|
By:
|
/s/ GAYN ERICKSON | |
| Gayn Erickson | |||
| President and Chief Executive Officer | |||
|
Date: October 15, 2013
|
By:
|
/s/ GARY L. LARSON | |
| Gary L. Larson | |||
| Vice President of Finance and | |||
| Chief Financial Officer |
|
Exhibit No.
|
Description
|
|
|
3.1(1)
|
Restated Articles of Incorporation of the Company.
|
|
|
3.2(2)
|
Amended and Restated Bylaws of the Company.
|
|
|
10.1(3)
|
Third Amendment to Loan and Security Agreement dated
August 21, 2013 by and between Aehr Test Systems and Silicon
Valley Bank.
|
|
|
10.2(4)
|
Third Amendment to Export-Import Bank Loan and Security
Agreement Dated August 21, 2013 by and between Aehr Test Systems
and Silicon Valley Bank.
|
|
|
Certification of Chief Executive Officer pursuant to Rules
13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended, as adopted pursuant to
Section 302(a) of the Sarbanes-Oxley Act of 2002.
|
||
|
Certification of Chief Financial Officer pursuant to Rules
13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended, as adopted pursuant to
Section 302(a) of the Sarbanes-Oxley Act of 2002.
|
||
|
Certification of Chief Executive Officer and Chief Financial
Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
|
||
|
101.INS
|
XBRL Instance Document**
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document**
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document**
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document**
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document**
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document**
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|